Carl Icahn

Biography

Carl Icahn (b. 1936) is the elder statesman of activist investing — the corporate raider of the 1980s who survived long enough to become an institution, and the man against whom Bill Ackman fought the most personal and most expensive battle of his career. Where Ackman came up through forensic research and public persuasion, Icahn came up through proxy fights, tender offers, and the threat of his own presence on a shareholder register. He ran his campaigns the old way: private, feared, and financed by a fortune large enough that he answered to no limited partner. By the time their paths crossed, he had been forcing CEOs to bend for three decades and had outlived every label thrown at him — raider, greenmailer, activist, icon.

From Ackman's vantage point, Icahn was never simply another investor with a different style. He was the representative of everything the younger man believed activism had to outgrow. Ackman's model — laid out across the Herbalife presentation and the Canadian Pacific campaign — was activist investing as public argument: exhaustive research, transparent reasoning, the market as jury. Icahn's model was activist investing as leverage: capital, intimidation, and staying power. Their collision over Herbalife was therefore never only about one stock. It was a live-fire test of two theories of what activism is for, fought by two men who already had a decade of bad blood behind them.

Relationship with Ackman

The relationship began in 2003, at the lowest point of Ackman's first career, and it began with a contract whose name alone explains everything that followed: "schmuck insurance." Ackman, winding down Gotham Partners under the shadow of the Spitzer investigation described in Confidence Game, sold Icahn his stake in Hallwood Realty at $80 a share, with a written side agreement entitling Gotham's investors to half of Icahn's profit if he sold within three years. When Hallwood was cashed out in a merger at $136, Icahn refused to pay, arguing he had never "sold." Ackman sued, won summary judgment, and then spent eight years collecting, as Icahn appealed at every level — waiting, Ackman later recalled, until day 179 of each appeal window before filing. The money was material to Gotham's last investors; to Icahn it was a rounding error. Ackman treated the fight as fiduciary duty and personal education at once: he had learned, he said on live television years later, the quintessential lesson that "on Wall Street if you want a friend get a dog" (CNBC, January 25, 2013).

At the time, Ackman saw Icahn as a bully who preyed on counterparties in weak positions — a man who had looked at a wounded young fund manager and calculated he would never have the resources to collect. The honesty of that view, formed in 2003, is essential to understanding 2013: when Icahn went long Herbalife against Ackman's short, Ackman never believed it was an analytical disagreement. He believed then, and said a decade later, that "his motivations here were not really principally driven by thinking Herbal Life was a good company" — it was an opportunity to hurt him (Lex Fridman podcast, 2024).

The view from the other side of the war, and the view from today, is more complicated. Ackman now describes an eight-year litigation punctuated by a dinner at Icahn's favorite Italian restaurant, an offer of $10 million to Ackman's favorite charity to settle — refused, because the money belonged to investors — and, eventually, a phone call in which Icahn proposed they be friends. In 2024, asked what he genuinely likes about the man, Ackman answered without hesitation: "he's funny he's charismatic he's got incredible stories." The two made peace publicly, embraced on CNBC, and Icahn has been a guest at Ackman's home. The arc of the relationship — counterparty, nemesis, and finally something close to affectionate respect — tracks Ackman's own four acts, and he is candid about the destination: "I kind of like the guy" (Lex Fridman podcast, 2024).

Key Episodes

The thesis (December 2012). Pershing Square unveiled a 334-slide presentation arguing Herbalife was a pyramid scheme whose revenues depended on endless recruitment rather than retail sales — the culmination of a year and a half of research and the purest expression of forensic shorting as Ackman then practiced it. Reasoned at the time, the case seemed asymmetric in his favor: if the FTC acted, the stock went to zero; meanwhile the position would, in his view, be carried by deteriorating fundamentals. What the thesis could not model was a motivated billionaire on the other side.

The brawl (January 25, 2013). One month in, with Icahn's long position still undisclosed, the two met live on CNBC's Halftime Report for roughly twenty-seven unscripted minutes that remain the most-watched segment in business television history. Icahn called in and reached immediately for 2003: Ackman was "the crybaby in the schoolyard," a man he rued ever meeting. Ackman, given the floor, rebuilt the Hallwood contract line by line and delivered his verdict: "this is not an honest guy and this is not a guy who keeps his word." Icahn predicted the short would end in "the mother of all short squeezes"; Ackman invited him to tender for the whole company. Neither man discussed the other's thesis. The full exchange is preserved in the CNBC transcript.

The war of attrition (2013–2016). Icahn then did what no rebuttal slide could: he bought. He disclosed a stake weeks after the broadcast, kept accumulating toward a quarter of the company, placed five directors on the board, and held for years while Herbalife borrowed billions to repurchase its own shares. For Ackman, this was the nightmare geometry of shorting made flesh — every Icahn purchase and every corporate buyback shrank the free float and raised the cost of being right. The 2014 annual report records the conviction still intact: the thesis "will collapse or otherwise be shut down by regulators" (PSH 2014 Annual Report). The 2016 report records the vindication that wasn't: the FTC filed a complaint alleging Herbalife operated illegally and extracted a settlement requiring what it called a "top to bottom" restructuring — yet the stock rose on the news, because settlement meant survival (PSH 2016 Annual Report). Being right about the company was proving worthless against being wrong about the float.

The capitulation (2017–2018). In late 2017 Pershing Square converted the short into put options to cap the downside, then exited. The post-mortem in the 2017 annual report is unusually direct about the mechanism of defeat: "we underestimated Herbalife's ability to access debt capital and use financial engineering" — engineering that, combined with Icahn's purchases, left only 22.7 million of 87.4 million shares in non-affiliate hands, so the price rose "without regard to fundamental value" (PSH 2017 Annual Report). After five years, the scorecard Ackman himself kept was simple: "he made a billion we lost a billion" (Lex Fridman podcast, 2024).

Legacy & Lessons

The Herbalife war cost Ackman roughly a billion dollars, five years, and a measure of his reputation — Herbalife's counterattack, he has said, meant opponents "tried to do everything to destroy my reputation," rummaging through his trash for ammunition. But its true legacy is doctrinal. The man who built the second act of his career on public campaigns against MBIA and Herbalife emerged from the valley with a settled conclusion: Pershing Square would no longer wage public short campaigns. He states the revised doctrine with characteristic economy: "we've only really shorted two companies the first one there's a book the second one there's a movie" — and, he adds, "we no longer short companies" (Lex Fridman podcast, 2024).

The deeper lesson was about the difference between being right and getting paid. MBIA worked because the instrument was asymmetric — credit default swaps with bounded cost and no squeeze risk. Herbalife failed because a common-stock short against a company whose float a rival can corner is a position whose losses are theoretically unlimited and practically psychological. Icahn did not refute the thesis; he made the thesis unholdable. That distinction — between analytical correctness and structural survivability — is now embedded in how Ackman thinks about volatility versus permanent loss and the risks he refuses to underwrite. There is even a postscript he notes with evident irony: had Pershing Square been able to stay short, the trade would eventually have made money, as Herbalife's market value collapsed years later. The market agreed with him in the end. It simply agreed too late to matter.

And there is a final lesson, the one that closes the war rather than the trade. Icahn himself exited Herbalife years afterward, reportedly below his own cost; the FTC settlement he fought to enable permanently restructured the company he defended. The most personal trade in hedge fund history produced no winner — only a resetting. Ackman's account of that moment is the war's true epitaph and one of the foundations of his fourth act: "you don't need to make it back the way you lost it" (Lex Fridman podcast, 2024). Pershing Square took the loss, refocused on long-only, quality-first investing, and rebuilt — while the two antagonists, improbably, became the kind of friends who hug on television. The rivalry that taught Ackman the limits of conviction also taught him the limits of grievance.